Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir for CMV Prophylaxis in Renal Transplant Patients
NCT00373165Phase 4Completed
- Sponsor
- Nephrologisches Zentrum Niedersachsen
- Start
- Aug 2000
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 4, randomised, open-label trial of ganciclovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Nephrologisches Zentrum Niedersachsen. Primary endpoints: Impact of CMV infection on graft function at 12 months, Incidence of CMV infection at 12 months and 4 more. Started Aug 2000; status: completed.
02
Drugs
ganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00373165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373165.